Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term azithromycin maintenance continuation versus withdrawal in COPD
NL-OMON49192Phase 4Terminated
- Sponsor
- Amphia Ziekenhuis
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of azithromycin in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Amphia Ziekenhuis. Primary endpoint: Time to first COPD exacerbation. Started May 2021; status: terminated.
02
Drugs
azithromycin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON49192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49192.